Epigenetics of cancer and changes in DNA modification in tumours
16 Jul 2012
Epigenetics of cancer and changes in DNA modification in tumours
Perifosine disappoints in refractory mCRC
Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment
Advances in radiotherapy for rectal cancer
A new direction for development of targeted cancer therapies
Application of next generation sequencing
Next generation sequencing and WIN therapeutics
Identifying targets with systems medicine
Shortening the timeline for clinical drug developments
Building international collaborations and the WINTHER trial
GFI is crucial for AML1-ETO induced acute myeloid leukemia
Signaling and targeting cellular pathways in leukaemia metabolism